Angiogenic GENe Therapy (AGENT) trial in patients with stable angina pectoris | |
Article | |
关键词: CORONARY-ARTERY DISEASE; ENDOTHELIAL GROWTH-FACTOR; VEGF121 CDNA; BLOOD-FLOW; IN-VIVO; ANGIOPLASTY; HEART; ISCHEMIA; VECTORS; | |
DOI : 10.1161/hc1102.105595 | |
来源: SCIE |
【 摘 要 】
Background-The angiogenic response to myocardial ischemia can be augmented in animal models by gene transfer with the use of a replication defective adenovirus (Ad) containing a human fibroblast growth factor (FGF) gene. Methods and Results-The objectives of the Angiogenic GENe Therapy (AGENT) trial were to evaluate the safety and anti-ischemic effects of 5 ascending doses of Ad5-FGF4 in patients with angina and to select potentially safe and effective doses for subsequent study. Seventy-nine patients with chronic stable angina Canadian Cardiovascular Society class 2 or 3 underwent double-blind randomization (1:3) to placebo (n=19) or Ad5-FGF4 (n=60). Safety evaluations were performed at each visit and exercise treadmill testing (ETT) at baseline and at 4 and 12 weeks. Single intracoronary administration of Ad5-FGF4 seemed to be safe and well tolerated with no immediate adverse events. Fever of <1-day duration occurred in 3 patients in the highest-dose group. Transient, asymptomatic elevations in liver enzymes occurred in 2 patients in lower-dose groups. Serious adverse events during follow-up (mean, 3 11 days) were not different between placebo and Ad5-FGF4. Overall, patients who received Ad5-FGF4 tended to have greater improvements in exercise time at 4 weeks (1.3 versus 0.7 minutes., P=NS, n=79). A protocol-specified, subgroup analysis showed the greatest improvement in patients with baseline ETT less than or equal to10 minutes (1.6 versus 0.6 minutes, P=0.01, n=50). Conclusions-Results show evidence of favorable anti-ischemic effects with Ad5-FGF4 compared with placebo, and it appears to be safe. Angiogenic gene transfer with Ad5-FGF4 shows promise as a new therapeutic approach to the treatment of angina pectoris.
【 授权许可】
Free